Syros Pharmaceuticals Receives a Hold from H.C. Wainwright

By Austin Angelo

H.C. Wainwright analyst Andrew Fein maintained a Hold rating on Syros Pharmaceuticals (NASDAQ: SYRS) today and set a price target of $10. The company’s shares closed yesterday at $12.77.

Fein said:

“We point out that in preclinical studies, responses were observed in 59% (10/17) of PDX models tested, which would represent significant improvement over current therapies if this response rate translates into the clinics; (2) in combination with carboplatin in relapsed ovarian cancer with prior platinum-based therapy, who are still sensitive to platinum therapy (platinum-free interval of more than six months, n=24). In general, platinum-sensitive patients are more likely to respond to retreatment with a chemotherapy regiment that contains a platinum agent (e.g., carboplatin, cisplatin).”

According to, Fein is a 4-star analyst with an average return of 7.4% and a 52.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.

Syros Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $19.

See today’s analyst top recommended stocks >>

Based on Syros Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $14.46 million. In comparison, last year the company had a GAAP net loss of $11.52 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.